Insilico Medicine Doses First Patient in Generative AI‑Driven Phase III IPF Trial

Insilico Medicine administered the inaugural dose of its GENESIS‑IPF‑3 candidate to a patient, marking the first‑ever Phase III study of a drug designed using generative artificial intelligence. The trial targets idiopathic pulmonary fibrosis and follows earlier pre‑clinical success reported by the company.

GENESIS‑IPF‑3 is described as an innovative therapy created through AI algorithms that generate novel molecular structures, aiming to improve lung function and slow disease progression. Researchers hope the AI approach will shorten development timelines and lower costs compared with traditional methods.

AI in Drug Discovery market analysts project rapid expansion to 2035, driven by faster R&D cycles, precision medicine demands, and rising biopharma investment, while the pharma sector broadly doubles down on AI to slash expenses and accelerate pipelines.

Industry Observers note that successful outcomes could validate generative AI as a mainstream tool for creating therapies, potentially reshaping regulatory pathways and encouraging further investment in AI‑driven biotech ventures.